BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mohammadkhani A, James MH, Pantazis CB, Aston-Jones G. Persistent effects of the orexin-1 receptor antagonist SB-334867 on motivation for the fast acting opioid remifentanil. Brain Res 2020;1731:146461. [PMID: 31526801 DOI: 10.1016/j.brainres.2019.146461] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Yaeger JD, Krupp KT, Gale JJ, Summers CH. Counterbalanced microcircuits for Orx1 and Orx2 regulation of stress reactivity. Medicine in Drug Discovery 2020;8:100059. [DOI: 10.1016/j.medidd.2020.100059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 James MH, Fragale JE, Aurora RN, Cooperman NA, Langleben DD, Aston-Jones G. Repurposing the dual orexin receptor antagonist suvorexant for the treatment of opioid use disorder: why sleep on this any longer? Neuropsychopharmacology 2020;45:717-9. [PMID: 31986520 DOI: 10.1038/s41386-020-0619-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
3 Matzeu A, Martin-Fardon R. Targeting the orexin system for prescription opioid use disorder: Orexin-1 receptor blockade prevents oxycodone taking and seeking in rats. Neuropharmacology 2020;164:107906. [PMID: 31841797 DOI: 10.1016/j.neuropharm.2019.107906] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
4 Mehr JB, Mitchison D, Bowrey HE, James MH. Sleep dysregulation in binge eating disorder and "food addiction": the orexin (hypocretin) system as a potential neurobiological link. Neuropsychopharmacology 2021. [PMID: 34145404 DOI: 10.1038/s41386-021-01052-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Prasad AA, McNally GP. The ventral pallidum and relapse in alcohol seeking. Br J Pharmacol 2020;177:3855-64. [PMID: 32557550 DOI: 10.1111/bph.15160] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
6 Gamble MC, Katsuki F, McCoy JG, Strecker RE, McKenna JT. The Dual Orexin Receptor Antagonist DORA-22 Improves Mild Stress-induced Sleep Disruption During the Natural Sleep Phase of Nocturnal Rats. Neuroscience 2021;463:30-44. [PMID: 33737028 DOI: 10.1016/j.neuroscience.2021.03.003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 James MH, Aston-Jones G. Introduction to the Special Issue: "Making orexin-based therapies for addiction a reality: What are the steps from here?". Brain Res 2020;1731:146665. [PMID: 31930996 DOI: 10.1016/j.brainres.2020.146665] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
8 Matzeu A, Martin-Fardon R. Targeting the Orexin System for Prescription Opioid Use Disorder. Brain Sci 2020;10:E226. [PMID: 32290110 DOI: 10.3390/brainsci10040226] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
9 Matzeu A, Martin-fardon R. Understanding the Role of Orexin Neuropeptides in Drug Addiction: Preclinical Studies and Translational Value. Front Behav Neurosci 2022;15:787595. [DOI: 10.3389/fnbeh.2021.787595] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Freeman LR, Bentzley BS, James MH, Aston-Jones G. Sex Differences in Demand for Highly Palatable Foods: Role of the Orexin System. Int J Neuropsychopharmacol 2021;24:54-63. [PMID: 32496559 DOI: 10.1093/ijnp/pyaa040] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
11 Williams DL, Coiduras II, Parise EM, Maske CB. Hindbrain orexin 1 receptors blunt intake suppression by gastrointestinal nutrients and cholecystokinin in male rats. Peptides 2020;133:170351. [PMID: 32579900 DOI: 10.1016/j.peptides.2020.170351] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Brown RM, Dayas CV, James MH, Smith RJ. New directions in modelling dysregulated reward seeking for food and drugs. Neurosci Biobehav Rev 2021:S0149-7634(21)00485-1. [PMID: 34736883 DOI: 10.1016/j.neubiorev.2021.10.043] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 McConnell SA, Brandner AJ, Blank BA, Kearns DN, Koob GF, Vendruscolo LF, Tunstall BJ. Demand for fentanyl becomes inelastic following extended access to fentanyl vapor self-administration. Neuropharmacology 2021;182:108355. [PMID: 33091459 DOI: 10.1016/j.neuropharm.2020.108355] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
14 Fragale JE, James MH, Avila JA, Spaeth AM, Aurora RN, Langleben D, Aston-Jones G. The Insomnia-Addiction Positive Feedback Loop: Role of the Orexin System. Front Neurol Neurosci 2021;45:117-27. [PMID: 34052815 DOI: 10.1159/000514965] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 James MH, Fragale JE, O'Connor SL, Zimmer BA, Aston-Jones G. The orexin (hypocretin) neuropeptide system is a target for novel therapeutics to treat cocaine use disorder with alcohol coabuse. Neuropharmacology 2021;183:108359. [PMID: 33091458 DOI: 10.1016/j.neuropharm.2020.108359] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
16 O'connor RM, Kenny PJ. Utility of ‘substance use disorder’ as a heuristic for understanding overeating and obesity. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2022. [DOI: 10.1016/j.pnpbp.2022.110580] [Reference Citation Analysis]
17 Kupchik YM, Prasad AA. Ventral pallidum cellular and pathway specificity in drug seeking. Neurosci Biobehav Rev 2021;131:373-86. [PMID: 34562544 DOI: 10.1016/j.neubiorev.2021.09.007] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Wiskerke J, James MH, Aston-Jones G. The orexin-1 receptor antagonist SB-334867 reduces motivation, but not inhibitory control, in a rat stop signal task. Brain Res 2020;1731:146222. [PMID: 31002819 DOI: 10.1016/j.brainres.2019.04.017] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]